





SASTA SUNDAR

5 November 2024


About company

Sasta Sundar Healthbuddy Ltd is an Indian digital healthcare platform that provides a wide range of healthcare products and services, primarily focused on affordable medicine delivery. It operates as an online pharmacy, offering discounted medicines, healthcare products, wellness items, and diagnostic services. Sasta Sundar partners with local pharmacies and uses a network-driven model to reach customers across India. The platform emphasizes quality, affordability, and accessibility, aiming to make healthcare more affordable and convenient.

Financials



MARKET CAP	RS 1,066 Cr.
P/E RATIO	28.1
DIVIDEND YIELD	0.00%
ROCE	-2.95%
ROE	0.77%
FACE VALUE	10.00
3 YEARS SALES GROWTH	38%
3 YEARS PROFIT GROWTH	37%



Our recommendation

MOMENTUM SWING: BUY SASTA SUNDAR BETWEEN 332-335 TARGETS 355-388 STOP LOSS BELOW 308

Technical analysis

The chart for Sastasundar Ventures Ltd. on a 1-hour timeframe shows a bullish trend with recent price action breaking above previous resistance levels. The stock is trading above the 20-period EMA (Exponential Moving Average), suggesting short-term upward momentum. The Supertrend indicator is in a buy zone, reinforcing the bullish sentiment. If we look at fundamentals 3 years CAGR of sales and profit stands at 38% and 37% respectively. Hence we recommended to buy Sasta Sundar Venture.



Disclaimer

I, Ruchi Nahar, SEBI Registered Research Analyst (INH000014544) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified CA, CS and MBA, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverage my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.